Estée Lauder CEO Stéphane de La Faverie says the firm’s fragrance performance is ‘one, if not the best’ in the industry, with organic sales up 20% and operating income up 93% in the fiscal first ...

Inovio sets a $460,000 list price for a full course of Voceryq, its first approved DNA medicine and the second approved to treat recurrent respiratory papillomatosis.

The company declined to publicly disclose the price of the new breast cancer treatment, but the US WAC is $24,392 for a monthly supply, according to a filing with the Vermont Attorney General.

LIB Therapeutics will launch its autoinjector for once-monthly Lerochol (lerodalcibep), available now in a prefilled syringe, with a $300 monthly list price – the lowest of the PCSK9 inhibitor class.

FDA’s practice of deciding forfeiture only when a later applicant seeks approval leaves first-filers guessing for years, industry reps say during an AAM conference session on potential GDUFA ...

Pharmacies may compound six unapproved peptides if they meet conditions on labeling, manufacturing and safety reporting, but the interim policy does not address how the products are advertised or ...

The FAST-EU pilot is accelerating the review of multinational clinical trial applications as intended, but the high ...

Indonesia’s Ministry of Health told the Asia-Pacific self-care congress that it is fully committed to self-care, as new rules ...

After the 2000s neuroprotection failures, stroke drug development is reviving. Scp776 (IGF-1) and loberamisal show early ...

Although Touchland, available in distinctive packaging and scents, “kind of created a category that didn't really exist,” ...

Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter ...

The FDA has classified Werfen’s recall of four lots of its HemosIL AcuStar HIT diagnostic test as Class I after performance issues raised concerns about false-negative results that could delay ...